Neuroprotective Effects of Hydrogen Sulfide in Parkinson’s Disease
Yang Ye,Jinhui Xu,Haitao Shen,Zhengquan Yu,Gang Chen
DOI: https://doi.org/10.4103/2045-9912.385945
2023-01-01
Medical Gas Research
Abstract:Hydrogen sulfide (H2S) has been considered to be a toxic gas with a rotten egg smell for decades. However, over the past two decades, many studies have shown that H2S has many pathological and physiological effects on mammalian body systems as a third endogenous gaseous mediator along with carbon monoxide and nitric oxide.[1] H2S is a sulfur analog of water molecules in structure and can be oxidized to the elements sulfur, thiosulfate, sulfate, and sulfur dioxide.[2] Low dose and controlled release of hydrogen sulfide can improve the function of a variety of immune cells and protect them from dysfunction caused by various harmful stimuli, such as reactive oxygen species (ROS) or oxidized low-density lipoprotein. These effects of H2S help maintain immune function, stimulate antibacterial defense and play an anti-inflammatory role in various diseases.[3] Studies show neuroprotective function of H2S in several central nervous system diseases including Parkinson's disease (PD), ischemic stroke, traumatic brain injury and Alzheimer's disease.[4,5] Both in vivo and in vitro, H2S has been demonstrated to exert antioxidant, anti-inflammatory and anti-apoptotic effects under pathological conditions.[6] H2S promotes the induction of long-term enhancement in the hippocampus by enhancing the activity of N-methyl-D-aspartate receptor, and then forms a synaptic model of memory. H2S can also increase the concentration of Ca2+ in glial cells, induce Ca2+ waves and mediate the transmission of glial signals.[7] H2S significantly reduced the severity of neuroinflammation in the rat model of traumatic brain injury and restored the neurotrophic factors that characterize the secondary events of traumatic brain injury.[8] Endogenous H2S synthesis decreases after intracerebral hemorrhage, and H2S can reduce secondary brain injury caused by neuroinflammatory response by inhibiting P2X7 receptor.[9] After intracerebral hemorrhage, sodium hydrogen sulfide (NaHS) supplementation can increase the production of endogenous H2S. In the Morris water maze test, H2S reduces brain edema, lesion volume and neurological deficit after intracerebral hemorrhage.[10] PD is the second most common neurodegenerative disease after Alzheimer's disease. According to statistics, approximately 2% of the global population over the age of 65 years is affected by PD.[11] The number of patients is expected to increase from 8.7 million to 9.3 million by 2030.[12] High-risk factors for PD include consumption of dairy products, exposure to pesticides, history of melanoma, and traumatic brain injury, while caffeine, smoking, physical activity, higher serum urate concentrations, and use of ibuprofen and other common medications can reduce the incidence of the disease.[13] Typical symptoms of PD include bradykinesia, rigidity, postural instability and resting tremor. The main pathological mechanism of these symptoms is the massive loss of dopaminergic neurons in the substantia nigra pars compacta.[14] The typical pathological features of PD are the loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded α-synuclein, which is present in intracytoplasmic inclusions called Lewy bodies.[15] In general, the first-class drug for PD is levodopa, but it only improves the symptoms, not the loss of dopaminergic neurons. One possible mechanism is oxidative stress-induced neuronal loss, including oxidation of levodopa, and the other is neurotoxins produced by activated microglia and astrocytes.[16] Treatment for PD is symptomatic, with an emphasis on improving nonmotor (e.g., cognition, mood, sleep, constipation) and motor (e.g., rigidity, tremor, bradykinesia) signs and symptoms.[17] There is no drug treatment that improves the disease. Therefore, it is important to develop effective therapeutic drugs or strategies that can reverse disease progression.[18] Various in vivo and in vitro PD models have demonstrated that supplementation of H2S reverses the loss of dopaminergic neurons and attenuates dyskinesia in PD patients.[5] The production and physiological role of endogenous H2S: The expression of H2S-catalyzed enzymes in the cardiovascular system, neuronal system, immune system, renal system, respiratory system, gastrointestinal system, reproductive system, liver system and endocrine system varies widely.[19] The synthesis of endogenous H2S in mammals mainly depends on three enzymes including cystathionine β synthase (CBS), cystathionine γ-lyase (CSE) and 3-mercaptopyruvate sulfur transferase, which convert cysteine or cysteine derivatives into H2S in different tissues and organs.[20] CSE and CBS are key enzymes in the reverse transsulfuration pathway, which results in sulfur transfer from homocysteine to cysteine. CSE and CBS generate H2S through several different reactions.[21] CSE can use homocysteine or cysteine to produce H2S with the help of 5-neneneba pyridoxal phosphate. CBS produces H2S not only through cysteine, but also through the combination of cysteine and homocysteine. CBS can also produce H2S from homocysteine alone, but the enzyme activity of CBS is inhibited when homocysteine levels are high. 3-Mercaptopyruvate sulfur transferase works with cysteine aminotransferase to produce H2S.[22] CBS is found primarily in cerebellar Bergmann glia and astrocytes in the brain. Transforming growth factor-α, epidermal growth factor, cyclic adenosine phosphate and dexamethasone promote CBS expression in astrocytes. In addition, S-adenosyl methionine as a CBS activator can also promote the enzymatic production of H2S.[23] One study showed that in the central nervous system, CBS was highly expressed only in astrocytes compared to microglia and neurons. In vitro, astrocytes synthesize H2S 7.57 times faster than microglia.[24] A study by Li et al.[25] found that H2S improves silent information regulator 1 activity by accelerating SIRT sulfation, thereby increasing autophagic flux and attenuating 1-methyl-4-phenylpyridinium-induced damage in SH-SY5Y cells. H2S acts as a neuromodulator and alters hippocampal long-term potentiation by selectively enhancing N-methyl-D-aspartate receptor-mediated currents in a memory synapse model.[26] Physiological concentrations of H2S increase cyclic adenosine phosphate production with downstream effects on camp stimulated intracellular pathways in brain cells, neurons and glial cell lines.[27] H2S induces calcium waves/elevation in both astrocytes and microglia.[28] Mechanisms of H2S in preventing the progression of PD: Anti-oxidative stress: Oxidative stress is the result of ROS-mediated damage to biological macromolecules and is a major factor in inflammation, cardiovascular diseases, neurodegenerative diseases, diabetes, atherosclerosis, aging, etc.[29] Oxidative phosphorylation is a major energy source for many cells, and endogenous ROS are by-products of oxidative phosphorylation. ROS are generated when oxidative phosphorylation is inefficient, resulting in oxidative stress that affects mitochondrial metabolism. In the central nervous system, oxidative stress leads to protein oxidation, lipid peroxidation, and mitochondrial DNA mutations that lead to neuronal cell death.[30] Glutathione is a major intracellular antioxidant, and oxidative stress reduces its concentration. H2S supplements glutathione levels, especially reduced glutathione, by increasing the activity of cystine/glutamate antiporters and cysteine transporters, thereby increasing the intracellular concentration of cysteine, which is the substrate for the production of glutathione.[31] H2S produced in mitochondria can directly inhibit oxidative stress.[32] In a study by Tang et al.,[33] 1-methy-4-phenylpyridinium ion (MPP+) promoted the production of ROS, particularly superoxide anion, and H2S attenuated MPP+-induced ROS accumulation. Inhibition of CBS activity and H2S production promotes ROS accumulation. Nicotinamide adenine dinucleotide phosphate oxidase produces neurotoxic oxidative stress, which is commonly thought to be involved in neurodegenerative diseases. A study by Hu et al.[34] in 2010 found that H2S can reduce 6-hydroxydopamine (6-OHDA)-induced ROS production through inhibiting nicotinamide adenine dinucleotide phosphate oxidase, thereby protecting neurons from 6-OHDA-induced damage. MPP+ induced SH-SY5Y cells to produce a large number of oxidative stress related factors such as malondialdehyde and ROS, while NaHS pretreatment could antagonize the increase in ROS and malondialdehyde levels. The levels of reduced glutathione and superoxide dismutase decreased after MPP+ induction. NaHS pretreatment could significantly reduce the consumption of glutathione induced by MPP+.[11] Anti-apoptosis: A study by Jiao et al.[35] in 2019 found that H2S significantly reduced the expression of Caspase 3 and Caspase 9 by inhibiting the activation of the nuclear factor kappa-B signaling pathway and the release of cytokines in PD rats, thereby reducing cell apoptosis. Lu et al.[18] found that H2S reversed the up-regulated protein expression of glucose-regulated protein 78, C/EBP homologous protein, and Caspase 12 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. However, these apoptosis-related proteins were still up-regulated when uncoupling protein 2 was knocked out.[18] Caspase 3 and Bcl-2/Bax ratio are both important biomarkers for evaluating MPP+ mediated apoptosis. Activated Caspase 3 is a key molecule in apoptosis and is involved in growth stimulation.[36] After treatment with MPP+, the activity of Caspase 3 was up-regulated and the Bcl-2/Bax ratio was decreased. Pretreatment with 200 μM NaHS significantly reduced MPP+-induced Caspase 3 activity and prevented the reduction of Bcl-2/Bax ratio.[11] Hu et al.[28] found that H2S can inhibit apoptosis by regulating K-ATP channel/p38- and c-Jun N-terminal kinase/ mitogen-activated protein kinase pathways in rotenone-induced PD model in vitro. Anti-inflammatory: Neuroscientists found a link between brain degeneration and persistent inflammation after collecting data from studies in the general field of neurodegenerative diseases.[37] Classical activation of microglia (resident mononuclear phagocytes of the central nervous system) has been observed in the brains of patients with PD and can be experimentally triggered by alpha-synuclein. Although activation of microglia is required to maintain the integrity of the central nervous system, unregulated inflammatory responses and the release of pro-inflammatory cytokines and ROS can also lead to neurotoxicity, such as reduced neurogenesis, resulting in neuronal loss and altered neuronal patterns of synaptic plasticity.[38] NaSH (H2S donor) not only inhibited the up-regulated expression of microglial activation marker ED-1 in PD rats, but also reduced the accumulation of rotenone-induced inflammatory factors including NOx (NO3− and NO2−) and tumor necrosis factor-α in rat striatum. Therefore, NaHS may inhibit the progression of PD by reducing microglia activation.[34] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine increased the number of activated microglias and astrocytes in the substantia nigra and, in the striatum, the number of activated microglias. Inhalation of H2S prevented 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced activation of microglia and astrocytes.[16,39,40] H2S reduces the activation of microglia, astrocytes and inflammatory factors released by THP-1 and U373 cell lines, including tumor necrosis factor-α, interleukin-6 and nitric oxide. H2S released from L-dopa hybrid molecule also inhibits monoamine oxidase B activity. Therefore, the anti-inflammatory and antioxidant effects of H2S may have a therapeutic effect on PD.[16] Other possible mechanisms: Xie et al.[41] found that H2S significantly reduced 6-OHDA-induced endoplasmic reticulum stress responses, including upregulation of eukaryotic initiation factor-2a phosphorylation levels, glucose-regulated protein 78 and C/EBP homologous protein expression. H2S inhibits endoplasmic reticulum stress primarily by blocking Akt activity with Akt inhibitors or by inhibiting heat shock protein 90 with geldanamycin. The decrease in Akt activity also reduced the protein abundance of heat shock protein 90 in SH-SY5Y cells. Therefore, H2S may reduce the damage caused by 6-OHDA-induced endoplasmic reticulum stress through the Akt-heat shock protein 90 pathway.[41] Glucose-regulated protein 78 and C/EBP homologous protein are endoplasmic reticulum stress-related proteins. Minaei et al.[14] confirmed by immunohistochemistry and western blot that 6-OHDA causes high expression of these two cells in rat striatum, and NaHS treatment can reduce the overexpression of these proteins by more than 60% (Figure 1).Figure 1:: H2S protects dopaminergic neurons in animal models through anti-inflammation, anti-apoptosis, anti-oxidative stress and anti-ER stress.Note: Created by Figdraw. AKT: Protein kinase B; CHOP: C/EBP homologous protein; ER: endoplasmic reticulum; GRP78: glucose-regulated protein 78; H2S: hydrogen sulfide; Hsp90: heat shock protein 90; MDA: malondialdehyde; NAPDH: nicotinamide adenine dinucleotide phosphate; NF-κB: nuclear factor kappa-B; ROS: reactive oxygen species; UCP2: uncoupling protein 2.Current limitations: Although H2S has neuroprotective effects and is a promising treatment for central neurodegenerative diseases, there are still many difficulties before it can be put into clinical use. Many studies have shown that H2S has beneficial effects at physiological concentrations, but harmful effects at higher concentrations.[11,42] Therefore, the treatment window of H2S is narrow, and it is difficult to maintain a relatively stable concentration of H2S in the brain. Several inhibitors of H2S synthesis in common use today, such as AOAA and hydroxylamine, are not specific to H2S biosynthesis and may be involved in other physiological functions. Although H2S has been shown to be beneficial in PD rat models, specific concentrations of H2S in the rat substantia nigra and striatum are currently difficult to detect.[4,43] Currently commonly used H2S donors are aqueous solutions of sodium sulfide (Na2S) and NaHS. However, the release H2S from these sulfide salts is spontaneous and rapid, making the delivered concentration of H2S difficult to control. Several synthetic donors capable of releasing H2S under physiological conditions have been reported to be developed but have not yet been used in PD-related studies.[20] Conclusion: Increasing evidence has shown that H2S has a neuroprotective effect on many degenerative diseases of the central nervous system, such as PD. PD is the second most common neurodegenerative disease in the world. Currently, drug treatment focuses mainly on symptom control and cannot effectively reverse the disease process. Therefore, it is very important to develop new treatment options. This article reviews the basic research on H2S in PD in recent years. H2S reduces or even reverses the apoptosis of dopaminergic neurons in animal models through anti-inflammatory, anti-apoptotic, and anti-oxidative stress, and improves behavioral function, indicating the therapeutic potential of H2S. However, current technology cannot detect the concentration of H2S in the substantia nigra and striatum in real time, nor can it allow the stable release of H2S in the brain. There are still many difficulties to overcome before H2S can be used in clinical practice. Gang Chen is an Editorial Board member of Medical Gas Research. He is blinded from reviewing or making decisions on the manuscript. The article was subject to the journal 's standard procedures, with peer review handled independently of this Editorial Board member and his research group.